Galectin Therapeutics (GALT) Cash from Operations (2010 - 2026)

Galectin Therapeutics' Cash from Operations history runs 17 years deep, the most recent figure standing at 3866000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations rose 49.72% year-over-year to 3866000.0 in Q1 2026; TTM through Mar 2026 was 20077000.0, a 46.25% increase from a year earlier, with the FY2025 full-year figure at 23900000.0, up 42.78% from the prior year.
• Cash from Operations grew to 3866000.0 in Q1 2026 per GALT's latest filing, from 6100000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 3500000.0 in Q3 2025 and bottomed at 12791000.0 in Q4 2024.
• The 5-year median for Cash from Operations is 7689000.0 (2025), against an average of 7858176.47.
• Across the five-year window, Cash from Operations sank 170.02% in 2024 and soared 59.19% in 2025, its largest moves.
• Year by year, Cash from Operations stood at 7239000.0 in 2022, then surged by 34.56% to 4737000.0 in 2023, then sank by 170.02% to 12791000.0 in 2024, then surged by 52.31% to 6100000.0 in 2025, then soared by 36.62% to 3866000.0 in 2026.
• Per Business Quant, the three latest GALT Cash from Operations figures stand at 3866000.0 (Q1 2026), 6100000.0 (Q4 2025), and 3500000.0 (Q3 2025).